Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Progenics Pharmaceuticals, Inc. ((PGNX - Snapshot Report)) reported third-quarter 2013 loss of 17 cents per share, narrower than the Zacks Consensus Estimate of a loss of 21 cents and the year-ago loss of 33 cents.

Quarter in Detail

Quarterly revenues were $0.9 million in the reported quarter, below the revenues of $1.1 million in the year-ago quarter. Revenues were also lower than the Zacks Consensus Estimate of $2 million.

Research and development (R&D) expenses remained flat at $8.1 million year over year. G&A expenses decreased 22% to $3.1 million.

Global sales of Relistor, the sole marketed product at Progenics, came in at $4.8 million, down 2% year over year, as reported by partner Salix Pharmaceuticals Ltd. ((SLXP - Analyst Report)). Worldwide net sales of Relistor were down 39% from the second quarter of 2013.

Relistor is a subcutaneous injection that is currently approved for the treatment of opioid-induced constipation (OIC) in patients with advanced illness receiving palliative care, when response to laxative therapy is inadequate. 

Progenics has a license agreement with Salix for the development and commercialization of Relistor worldwide except in Japan, where Progenics has licensed the rights to the subcutaneous formulation to Ono Pharmaceuticals Co. Ltd. .

An advisory panel of the FDA is expected to meet in Mar 2014 to discuss Salix' supplemental New Drug Application (sNDA) for Relistor to treat OIC patients with chronic pain. This is in response to the complete response letter (CRL) from the FDA in Jul 2012 for the above sNDA.

An interesting candidate in Progenics pipeline is MIP-1404, a prostate-specific membrane antigen (PSMA) imaging agent. Progenics completed enrolment in a phase II study of MIP-1404 whose preliminary data is expected early next year.

Progenics carries a Zacks Rank #2 (Buy). Currently, Actelion Ltd. (ALIOF) looks well positioned with a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GRP IN DXYN 15.84 +7.90%
BOFI HLDG IN BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%